Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Rhea-AI Summary

Polyrizon (NASDAQ: PLRZ) has successfully closed a $17.0 million private placement of Ordinary Shares and warrants. The offering included 35,416,667 Ordinary Units priced at $0.48 per unit, with each unit comprising one Ordinary Share or Pre-Funded Warrant and one Series A Warrant.

The Series A Warrants, exercisable for 30 months after shareholder approval, have an initial exercise price of $1.20 per Ordinary Share. Pre-Funded Warrants are priced at $0.47999 with a $0.00001 exercise price. The company plans to use the proceeds for general corporate purposes and working capital.

Aegis Capital Corp. served as the exclusive placement agent. The securities were offered privately to accredited investors and are not registered under the Securities Act. Polyrizon has agreed to file registration statements with the SEC for the resale of the shares and warrant-exercisable shares.

Insights

Financial Analyst

Polyrizon's $17 million private placement represents a significant financial development for this micro-cap biotech. With a current market cap of just $2.15 million, this capital raise is approximately 8 times the company's entire market value - a substantial cash infusion that transforms their financial position.

The deal structure reveals important insights: units priced at $0.48 represent a 30% premium to the current $0.369 share price, suggesting strong investor confidence despite the company's small size. The Series A warrants with a $1.20 exercise price (more than triple the current share price) could provide additional future capital if exercised.

This financing addresses what was likely a critical capital need for Polyrizon. While dilution will occur, the premium pricing partially mitigates this concern. Without specific details on capital allocation beyond "general corporate purposes," investors should monitor how efficiently management deploys these funds to advance their intranasal hydrogel technology.

For a development-stage biotech company, securing capital at a premium significantly extends their operational runway, potentially allowing them to reach value-creating milestones without immediate financing pressure. The involvement of Aegis Capital as placement agent adds institutional credibility to the transaction.

RAANANA, ISRAEL, April 01, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a biotech company specializing in innovative intranasal hydrogels, today announced the closing of its previously announce private placement  of approximately $17.0 million of Ordinary Shares and/or pre-funded and investor warrants at a price of $0.48 per Ordinary Unit.

The offering consisted of the sale of 35,416,667 Ordinary Units (or Pre-Funded Units), each consisting of (i) one (1) Ordinary Share or Pre-Funded Warrant, and (ii) one (1) Series A Warrant to purchase one (1) Ordinary Share per warrant. The offering price per Ordinary Unit was $0.48 (or $0.47999 for each Pre-Funded Unit, which is equal to the offering price per Ordinary Unit sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants will be exercisable following shareholder approval and may be exercised at any time until exercised in full The initial exercise price of each Series A Warrant is $1.20 per Ordinary Share or pursuant to an alternative cashless exercise option. The Series A Warrants are exercisable following shareholder approval and will have a term of 30 months. The number of securities issuable under the Series A Warrants is subject to adjustment as described in more detail in the report on Form 6-K to be filed in connection with the offering.  

Aggregate gross proceeds to the Company were approximately $17.0 million. The transaction closed on April 1, 2025. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.

Aegis Capital Corp. acted as exclusive placement agent for the private placement. Greenberg Traurig, P.A. acted as counsel to the Company. Kaufman & Canoles, P.C. acted as counsel to Aegis Capital Corp.

The securities described above were sold in a private placement transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the Ordinary Shares and the Shares issuable upon exercise of the pre-funded warrants and warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Polyrizon Ltd.

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the intended use of proceeds from the offering. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

FAQ

How much did Polyrizon (PLRZ) raise in its April 2025 private placement?

Polyrizon raised approximately $17.0 million through the private placement of Ordinary Shares and warrants at $0.48 per Ordinary Unit.

What is the exercise price of PLRZ's Series A Warrants from the April 2025 offering?

The Series A Warrants have an initial exercise price of $1.20 per Ordinary Share with a 30-month term after shareholder approval.

How many Ordinary Units did PLRZ issue in the April 2025 private placement?

Polyrizon issued 35,416,667 Ordinary Units, each consisting of one Ordinary Share or Pre-Funded Warrant and one Series A Warrant.

What will Polyrizon (PLRZ) use the $17 million private placement proceeds for?

The company plans to use the net proceeds for general corporate purposes and working capital.